Abcuro Fails Phase II/III Myositis Study But Wants To Continue

 
• By Joseph Haas
  
Abcuro's Phase II/III study myositis study misses primary, key secondary endpoints (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D